{"id":594895,"date":"2022-04-06T18:32:01","date_gmt":"2022-04-06T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=594895"},"modified":"2022-04-06T18:32:01","modified_gmt":"2022-04-06T18:32:01","slug":"prostate-cancer-therapeutics-report-indepth-analysis-into-the-clinical-trials-emerging-drugs-and-treatment-outlook-companies-novartis-pfizer-innocrin-roche-advantagene-janssen-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-therapeutics-report-indepth-analysis-into-the-clinical-trials-emerging-drugs-and-treatment-outlook-companies-novartis-pfizer-innocrin-roche-advantagene-janssen-and-others_594895.html","title":{"rendered":"Prostate Cancer Therapeutics Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Treatment Outlook | Companies &#8211; Novartis, Pfizer, Innocrin, Roche, Advantagene, Janssen, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Prostate Cancer Therapeutics Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Treatment Outlook | Companies - Novartis, Pfizer, Innocrin, Roche, Advantagene, Janssen, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Prostate Cancer Therapeutics Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Treatment Outlook | Companies - Novartis, Pfizer, Innocrin, Roche, Advantagene, Janssen, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cProstate Cancer Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prostate Cancer Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Prostate Cancer Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Prostate Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/5bc4b042232774974ac2d15f19b7f9b5.jpg\" alt=\"Prostate Cancer Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Prostate Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Prostate Cancer<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for&nbsp;<strong>Prostate Cancer Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Prostate Cancer key companies <\/strong>involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211; @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prostate Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The available therapeutics treatment options in Prostate Cancer Landscape aim to provide cure to the patients suffering from this indication, however, there are several challenges that are yet to be tackled.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>As per DelveInsight, the Prostate Cancer market dynamics&nbsp;is anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of therapies for Prostate Cancer.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Companies in the Prostate Cancer Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Myovant Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pharmaceuticals USA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Astellas Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Innocrin Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Advantagene (Candel Therapeutics)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck Sharp &amp; Dohme<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And several other<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prostate Cancer Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lynparza<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Opdivo<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lutathera<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Relugolix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Niraparib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ipatasertib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Talazoparib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ProstAtak<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Keytruda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rucaparib<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Prostate Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Prostate Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Prostate Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Prostate Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Prostate Cancer Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Prostate Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Prostate Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Prostate Cancer Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Prostate Cancer Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Prostate Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Prostate Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Prostate Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/global-kinase-inhibitor-in-autoimmune-diseases-market\">Global Kinase Inhibitor in Autoimmune Diseases Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong>Global Kinase Inhibitor in Autoimmune Diseases&nbsp; Market<\/strong>&#8221; report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies operating in the domain.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=prostate-cancer-therapeutics-report-indepth-analysis-into-the-clinical-trials-emerging-drugs-and-treatment-outlook-companies-novartis-pfizer-innocrin-roche-advantagene-janssen-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=prostate-cancer-therapeutics-report-indepth-analysis-into-the-clinical-trials-emerging-drugs-and-treatment-outlook-companies-novartis-pfizer-innocrin-roche-advantagene-janssen-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cProstate Cancer Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prostate Cancer Market. The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-therapeutics-report-indepth-analysis-into-the-clinical-trials-emerging-drugs-and-treatment-outlook-companies-novartis-pfizer-innocrin-roche-advantagene-janssen-and-others_594895.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,406,403,404],"tags":[],"class_list":["post-594895","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/594895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=594895"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/594895\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=594895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=594895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=594895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}